ArticleFrontiers in oncology2022

Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study.

Jingzhu Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.